抗中性粒细胞胞质抗体相关性血管炎中利妥昔单抗与环磷酰胺诱导缓解策略对肾衰竭和死亡风险的比较有效性
基于Mass General Brigham AAV队列(2002年1月1日至2019年12月31日诊断的595例患者),比较利妥昔单抗与环磷酰胺诱导缓解策略对肾衰竭或死亡复合结局的长期风险。5年时两组风险相似:多变量校正分析HR 1.03(95%CI 0.55-1.93),倾向评分匹配分析HR 1.05(95%CI 0.55-1.99);1年、2年及按肾脏受累和严重程度分层的亚组结果相似。
要点
- 利妥昔单抗组与环磷酰胺组5年肾衰竭或死亡风险相似,多变量校正HR 1.03(95%CI 0.55-1.93)。
- 倾向评分匹配分析结果一致,HR 1.05(95%CI 0.55-1.99)。
- 1年、2年及按肾脏受累和严重程度分层的亚组结果与主分析相似。
核心结论
- 利妥昔单抗与环磷酰胺诱导缓解策略在AAV中与相似的肾衰竭和死亡风险相关。
研究设计与样本
- 采用Mass General Brigham AAV队列的队列研究,纳入2002年1月1日至2019年12月31日诊断的蛋白酶3-ANCA+和髓过氧化物酶(MPO)-ANCA+ AAV患者。
- 纳入初始诱导缓解策略为利妥昔单抗或环磷酰胺的病例,共595例;352例(约60%)接受利妥昔单抗方案,243例(约40%)接受环磷酰胺方案。
- 平均年龄61岁,58%为女性,70%为MPO-ANCA+,69%有肾脏受累(估算肾小球滤过率中位数37.3 ml/min/1.73 m2)。
- 使用多变量Cox比例风险模型和倾向评分匹配分析评估利妥昔单抗与环磷酰胺策略同肾衰竭或死亡复合结局的关联。
主要发现
- 5年时共133个事件,利妥昔单抗方案和环磷酰胺方案的发生率分别为6.8/100人年和6.1/100人年。
- 5年时肾衰竭或死亡风险在多变量校正分析中两组相似(HR 1.03,95%CI 0.55-1.93)。
- 5年时肾衰竭或死亡风险在倾向评分匹配分析中两组相似(HR 1.05,95%CI 0.55-1.99)。
- 1年和2年评估结局时结果相似,按肾脏受累和严重程度以及主要器官受累分层的亚组结果也相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare rituximab- versus cyclophosphamide-based remission induction strategies for the long-term risks of kidney failure and death in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in a real-world cohort. METHODS: We performed a cohort study using the Mass General Brigham AAV Cohort, which includes proteinase 3-ANCA+ and myeloperoxidase (MPO)-ANCA+ AAV patients diagnosed from January 1, 2002 to December 31, 2019. We included cases in which the initial remission induction strategy was based either on rituximab or cyclophosphamide. The primary outcome was the composite outcome of kidney failure or death. We used multivariable Cox proportional hazards models and propensity score-matched analyses to assess the association of rituximab- versus cyclophosphamide-based treatment strategies with the composite outcome of kidney failure or death. RESULTS: Of 595 included patients, 352 patients (~60%) received rituximab-based and 243 patients (~40%) received cyclophosphamide-based regimens. The mean age was 61 years, 58% of patients were female, 70% of patients were MPO-ANCA+, and 69% of patients had renal involvement (median estimated glomerular filtration rate 37.3 ml/minute/1.73 m2 ). There were 133 events at 5 years, and the incidence rates in rituximab- and cyclophosphamide-based regimens were 6.8 and 6.1 per 100 person-years, respectively. The risk of kidney failure or death was similar in both groups in multivariable-adjusted analyses (hazard ratio [HR] 1.03 [95% confidence interval (95% CI) 0.55-1.93]) and in propensity score-matched analyses (HR 1.05 [95% CI 0.55-1.99]) at 5 years. Our findings were similar when outcomes were assessed at 1 and 2 years as well as in subgroups stratified according to renal involvement and severity as well as major organ involvement. CONCLUSION: Rituximab- and cyclophosphamide-based remission induction strategies for AAV are associated with similar risks of kidney failure and death.
引用
- Wallace ZS, Fu X, Cook C, et al. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality. Arthritis Rheumatol. 2023. PMID: 37011036. doi:10.1002/art.42515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。